GET DAILY SIGNALSCorMedix (CRMD) Readies Q3 2026 Earnings Report as DefenCath Pricing Shifts
Key Takeaways
- CorMedix (CRMD) is expected to report third-quarter 2026 results on November 11, 2026, before the market opens, with a conference call scheduled for November 12.
- Consensus estimates call for revenue of roughly $52.8 million and a net loss of approximately $0.09 per share, reflecting a sharp expected decline from the prior-year quarter's $104.3 million in revenue and $1.26 diluted EPS.
- The anticipated pullback is largely driven by DefenCath's transition from TDAPA (Transitional Drug Add-on Payment Adjustment, a temporary Medicare reimbursement program) to lower post-TDAPA pricing, which management has flagged for the second half of 2026.
- CorMedix reaffirmed full-year 2026 revenue guidance of $325 million to $345 million and raised adjusted EBITDA guidance to $125 million to $140 million when it last reported in August 2026.
- Analysts maintain a Moderate Buy consensus rating with an average price target near $14.62, well above recent trading levels.
- For additional coverage, explore Major News, Today's Price Move, Price Targets, and Forecast pages for this ticker.
- Interested in automated trading insights? Explore Trending AI Robots for data-driven market signals.
Why This Quarter Carries Extra Weight
CorMedix's third-quarter report carries unusual weight because it marks the first full quarter reflecting DefenCath's move from the temporary TDAPA reimbursement period into the post-TDAPA add-on phase. During TDAPA, the company captured elevated per-unit pricing that powered record revenue and profitability; as that benefit phases out, investors are bracing for lower net pricing even as underlying volume demand continues. Management has already guided for this transition, but the market is watching closely to see whether volume growth and the acquired Melinta portfolio can offset the pricing reset. The quarter will test the durability of CorMedix's newly diversified, profitable business model following its August 2025 Melinta acquisition. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
Analysts expect CorMedix to report third-quarter 2026 revenue near $52.8 million, down roughly 49% from $104.3 million a year earlier, alongside a consensus net loss of about $0.09 per share compared with $1.26 diluted EPS in the prior-year period. These figures reflect a deliberate, well-telegraphed reset: in the second half of 2026, DefenCath transitions from TDAPA to a post-TDAPA add-on reimbursement amount that results in materially lower net selling prices per unit. For context, CorMedix posted $101.9 million in revenue and $0.29 diluted EPS in the second quarter of 2026, beating estimates, and has topped consensus EPS in seven of its last eight quarters. Beyond the headline figures, investors will scrutinize DefenCath unit volumes, Melinta portfolio sales, operating-expense discipline, and any updated commentary on full-year 2026 guidance of $325 million to $345 million in revenue and $125 million to $140 million in adjusted EBITDA. From what I see, the AI Daily Buy/Sell Signals tool helped flag similar reimbursement transitions in the sector earlier this year.
Market Sentiment Heading Into the Print
Sentiment heading into the report is cautious but constructive. The anticipated year-over-year revenue and EPS declines are widely understood to be a reimbursement artifact rather than a demand problem, and the stock has already repriced through much of 2026 as the TDAPA-to-add-on transition approached. Still, the gap between the roughly $14.62 average analyst price target and recent trading levels signals that many investors believe the market is undervaluing the company's volume trajectory and pipeline optionality. Key risk factors include greater-than-expected pricing pressure in the post-TDAPA phase, any slowdown in DefenCath ordering patterns, and slower progress on Medicare Advantage contracting, which management has excluded from 2026 guidance but views as a meaningful longer-term growth lever.
What to Watch Going Forward
Beyond the headline numbers, investors should watch several forward-looking signals. First is the trajectory of DefenCath volume and whether order patterns remain consistent with management's post-TDAPA forecasts; a pilot program with a newly signed large dialysis organization, covering roughly 200 clinics, is expected to begin in the third quarter, with potential expansion into 2027.
Second, reimbursement clarity matters. Management has indicated that, based on current CMS (Centers for Medicare & Medicaid Services) calculation methodology, the post-TDAPA add-on amount could rise significantly in 2027, potentially supporting a higher net selling price per unit next year relative to second-half 2026 estimates.
Third, keep an eye on the pipeline. CorMedix has reported positive Phase III ReSPECT data for REZZAYO in the prophylaxis of invasive fungal disease, with an sNDA submission planned for the third quarter of 2026 and potential FDA action in the first half of 2027. Success there would open a large additional market and diversify the company further beyond hemodialysis.
Finally, monitor expense discipline and cash generation. With a strong balance sheet, an integrated Melinta portfolio, and an expanding commercial organization, the company's ability to hold operating costs in check while funding pipeline investment will be central to sustaining the profitability narrative through the reimbursement transition. I’m watching this closely with help from the AI Trend Prediction Engine to gauge potential volume trends.
How AI Tools Fit Into My Research Routine
When preparing for earnings like this one, I often turn to Tickeron’s AI Screener to quickly filter healthcare names by technical patterns, fundamentals, and AI-driven signals. It lets me compare CRMD against peers in real time without manually sorting through dozens of data points, which saves time and highlights any overlooked opportunities in the biopharma space. The platform’s customizable filters for volatility, trends, and performance metrics have become a regular part of my workflow for catalyst-driven names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRMD's RSI Oscillator sits in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 230 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CRMD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CRMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (3.498). P/E Ratio (2.163) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical devices for cardiovascular and kidney diseases
Industry Biotechnology
Advertisement